You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動丨綠葉製藥(2186.HK)漲5.54% 阿爾茨海默病新藥在華進入臨牀試驗
格隆匯 09-02 15:04
格隆匯9月2日丨綠葉製藥(2186.HK)漲5.54%,報4.57港元,總市值148.5億港元。

綠葉製藥宣佈,其治療阿爾茨海默病的新藥——利斯的明透皮貼劑(多日貼,產品編號LY03013)已獲得中國國家藥品監督管理局藥品審評中心批准進入臨牀試驗。該藥物由德國子公司Luye Pharma AG的透皮釋藥技術平台開發,此前,其上市申請已獲得德國、英國等7個歐洲國家的正式受理,相關審評工作已在順利開展中。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account